In a July 17 memo, the agency proposed eliminating previous limits on Medicare coverage of the scans, which restricted their use to clinical trials.
The scans can detect beta amyloid plaques in the brain, which new treatments for the disease target.
The FDA approved Leqembi, Eisai and Biogen’s medication targeting amyloid plaques in the brain, July 6. CMS will cover the drugs for Medicare patients under certain conditions.
The proposal is open for comment until Aug. 16.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
